How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

13,775 results for

Ages and Stages Questionnaire

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Stages of Biological Development across Age: An Analysis of Canadian Health Measure Survey 2007–2011 Full Text available with Trip Pro

Stages of Biological Development across Age: An Analysis of Canadian Health Measure Survey 2007–2011 The stages of biological development are not clearly defined despite the fact that they have been used to refer to concepts such as adolescence and aging. This study aimed to (1) propose and test a framework to search for stages of representative components and determine stages of stability and transition, (2) identify stages of biological development based on health questionnaire (...) ) analysis was conducted to summarize the data and the loadings were used to interpret the PCs. A stable stage was assumed to be the age groups without significantly different values of PCs.The CHMS interviewed 16,340 Canadians. Of all, 51.25% were female. The age ranged from 6 to 79 years (mean = 34.41 years, 95% CI = 34.74-34.08). The proportions of total variance explained by the first three PCs were 12.14, 4.03, and 3.19%, respectively. The differences of the first PC were not significant, especially

2018 Frontiers in public health

22. Adequacy of nutrition and body weight in patients with early stage dementia: The cognition and aging study. (Abstract)

Adequacy of nutrition and body weight in patients with early stage dementia: The cognition and aging study. Recent evidence highlights the effects of obesity, diabetes and hypertension in the development of Alzheimer's disease. Involuntary body weight changes in patients with different stages of dementia can be related to clinical factors of the patient per se or support from their caregivers. Understanding the interactions among factors is important to establish a monitoring paradigm to guide (...) treatment strategies.A total of 345 patients with very mild (n = 224) and mild stage (n = 121) dementia were enrolled from a multi-disciplinary dementia clinic. Clinical data (comorbidities, Mini-Mental State Examination [MMSE] scores, neuropsychiatric inventory [NPI] scores, eating behavior questionnaire), nutritional state (Mini-Nutritional Assessment [MNA] or MNA short form [MNA-SF]) and body mass index (BMI) were recorded. Nutritional state and BMI served as the two major outcome measures

2018 Clinical nutrition (Edinburgh, Scotland)

23. Arabic Ages and Stages Questionnaire-III

Arabic Ages and Stages Questionnaire-III Arabic Ages and Stages Questionnaire-III - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Arabic Ages and Stages Questionnaire-III The safety and scientific validity (...) /treatment Child Development Behavioral: Arabic ASQ -3 Detailed Description: The Ages and Stages Questionnaires (ASQ) is a developmental screening questionnaire for parents to answer regarding their children's level of growth and development between the ages of 7 months and 3 years. This questionnaire was translated into Arabic in order to adapt it for the Arab speaking culture. For the first phase of this study, aiming to adapt and field-test this translated version, parents of eligible children

2015 Clinical Trials

24. Dutch norms for the Strengths and Difficulties Questionnaire (SDQ) – parent form for children aged 2–18 years Full Text available with Trip Pro

Dutch norms for the Strengths and Difficulties Questionnaire (SDQ) – parent form for children aged 2–18 years Identification of children at risk for psychosocial problems is important to be able to provide supportive and tailored care at an early stage. Due to its brevity and wide age range, the Strengths and Difficulties Questionnaire (SDQ) Parent Form is an appropriate instrument for use in paediatric clinical practice as it facilitates assessment of psychosocial functioning from young (...) childhood into adulthood. The aim of the present study was to provide Dutch normative data for the SDQ Parent Form.A sample of 1947 parents with children aged 2-18 years was drawn from a large panel of a Dutch research agency, stratified on Dutch key demographics of the parents. The SDQ Parent Form assesses the child's Emotional symptoms, Conduct problems, Hyperactivity-Inattention, Peer problems and Prosocial behaviour. Summary scores can be calculated: Internalising, Externalising and Total

2018 Health and quality of life outcomes

25. Association of Low Luminance Questionnaire With Objective Functional Measures in Early and Intermediate Age-Related Macular Degeneration. Full Text available with Trip Pro

Association of Low Luminance Questionnaire With Objective Functional Measures in Early and Intermediate Age-Related Macular Degeneration. To determine whether Low Luminance Questionnaire (LLQ) scores are associated with objective measures of visual function in early and intermediate age-related macular degeneration (AMD).Cross-sectional study of subjects with early AMD Age-Related Eye Disease Study (AREDS) stage 2, N = 33), intermediate AMD (AREDS stage 3, N = 47), and age-matched healthy

2018 Investigative Ophthalmology & Visual Science

26. Concurrent Validity of Ages and Stages Questionnaires in Preterm Infants Full Text available with Trip Pro

Concurrent Validity of Ages and Stages Questionnaires in Preterm Infants Although preterm infants born at 29 to 36 gestational weeks (GW) are at risk for developmental delay, they do not always benefit from systematic follow-up. Primary care physicians are then responsible for their developmental surveillance and need effective screening tests. This study aimed to determine whether the Ages and Stages Questionnaires (ASQ) at 12 and 24 months' corrected age (CA) identify developmental delay

2012 EvidenceUpdates

27. Diagnosis and Treatment of Early Stage Testicular Cancer

tumor marker (hCG, AFP and LDH) levels obtained prior to the initiation of chemotherapy, staging imaging studies, and tumor histology following radical orchiectomy (Strong Recommendation; Evidence Level: Grade A). Any post-pubertal male, regardless of age, should be treated according to adult treatment guidelines. (Moderate Recommendation; Evidence Level: Grade B) 17. For patients in whom serum tumor marker (AFP and hCG) levels are borderline elevated (within 3x upper limit of normal) post (...) populations 5,6 Age-adjusted incidence has nearly doubled over the last 4 decades for unknown reasons, from 3.7 per 100,000 in 1975 to 6.4 per 100,000 in 2014. 5 A stage migration of GCT has been observed, presumably due to increased awareness and earlier diagnosis. Between 1973 and 2014, the percentage of tumors diagnosed at a localized stage increased from 55% to 68% in the United States. Currently, less than 15% of men present with stage III disease (to the lungs, viscera, or non-regional lymph nodes

2019 American Urological Association

28. Dabrafenib (Tafinlar) - In combination with trametinib for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation

and often affects people of working age. Different activating mutations have been described in melanoma and approximately 45% of patients with cutaneous melanoma carry a BRAF V600 mutation. Melanoma can be curable if recognised and treated with surgery at an early stage however prognosis for patients with advanced melanoma is poor with 5- year survival between 40% and 80%. 3, 6 Interferon alfa is licensed in Scotland for the treatment of resected melanoma in the adjuvant setting, but is not recommended (...) Dabrafenib (Tafinlar) - In combination with trametinib for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation 1 Published 11 February 2019 1 SMC2131 dabrafenib 50mg and 75mg hard capsules (Tafinlar®) Novartis Pharmaceuticals UK Ltd In confidence 11 January 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland

2019 Scottish Medicines Consortium

29. ESMO–ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease

ESMO–ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease SPECIAL ARTICLE ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease † N. Colombo 1 * , C. Sessa 2 , A. du Bois 3 , J. Ledermann 4 , W. G. McCluggage 5 , I. McNeish 6 , P. Morice 7 , S. Pignata 8 , I. Ray-Coquard 9 , I (...) jointlydevelopedclinicallyrelevant andevidence-based recommendationsinseveralselectedareas inorderto improvethequalityofcare forwomenwithovariancancer. TheESMO– ESGO consensusconferenceonovariancancerwasheldon 12–14April2018inMilan,Italy,andcomprisedamultidisciplinary panelof 40leadingexpertsin themanagementofovariancancer. Beforetheconference,the expertpanel workedonfive clinically relevantquestions regardingovariancancerrelating toeachofthefollowingfour areas:pathologyandmolecular biology,early-stage andborderlinetumours

2019 European Society for Medical Oncology

30. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

, multicentre, double-blind, randomised, controlled, phase 3 trial. Eligible patients were aged at least 18 years, had a WHO performance status of 0 or 1, with histologically or cytologically documented stage III, unresectable non-small-cell lung cancer, for which they had received at least two cycles of platinum-based chemoradiotherapy, with no disease progression after this treatment. We randomly assigned patients (2:1) using an interactive voice response system and a blocked design (block size=3 (...) Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study Patient-reported Outcomes With Durvalumab After Chemoradiotherapy in Stage III, Unresectable Non-Small-Cell Lung Cancer (PACIFIC): A Randomised, Controlled, Phase 3 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed

2020 EvidenceUpdates

31. Questionnaires to measure asthma control in children aged 6-18 years in a primary care population

Questionnaires to measure asthma control in children aged 6-18 years in a primary care population Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external (...) or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured at multiple time points, data from the time point where efficacy is highest will be included. ">Methods for data extraction Example: Experimental groups, control group(s) and number of animals per group. ">Data to be extracted: study design Example: Species, sex, weight, age, co‐morbidity, anaesthetic agent used, method of induction of cardiac ischemia, duration of ischemia and duration

2019 PROSPERO

32. Diagnosis, staging and treatment of patients with Lung Cancer

not demonstrated an improvement in overall survival and is not recommended. (B) 2.6.5.3 In patients with stage IV NSCLC who do not experience disease progression after 4-6 cycles of platinum-based double agent chemotherapy, there is insufficient evidence to recommend maintenance therapy with erlotinib. (B) 2.6.6.1 In elderly patients (age 70-79 years) with stage IV NSCLC who have good performance status and limited co-morbidities, treatment with a platinum doublet chemotherapy is recommended. (B) 2.6.6.2 (...) In patients with stage IV NSCLC with a performance status of 2, single agent chemotherapy may be considered. Platinum doublet chemotherapy is suggested over single agent chemotherapy if the performance status of 2 is cancer related rather than co-morbidity associated. (B) 2.6.6.3 Unfit patients of any age (performance status (3-4)) do not benefit from cytotoxic chemotherapy. However if patients harbor an EGFR or ALK mutation positive tumour, they may be considered for treatment with targeted therapies. (C

2017 Health Service Executive (Ireland) - Clinical Guidelines

33. Diagnosis, staging and treatment of patients with lung cancer

not demonstrated an improvement in overall survival and is not recommended. (B) 2.6.5.3 In patients with stage IV NSCLC who do not experience disease progression after 4-6 cycles of platinum-based double agent chemotherapy, there is insufficient evidence to recommend maintenance therapy with erlotinib. (B) 2.6.6.1 In elderly patients (age 70-79 years) with stage IV NSCLC who have good performance status and limited co-morbidities, treatment with a platinum doublet chemotherapy is recommended. (B) 2.6.6.2 (...) In patients with stage IV NSCLC with a performance status of 2, single agent chemotherapy may be considered. Platinum doublet chemotherapy is suggested over single agent chemotherapy if the performance status of 2 is cancer related rather than co-morbidity associated. (B) 2.6.6.3 Unfit patients of any age (performance status (3-4)) do not benefit from cytotoxic chemotherapy. However if patients harbor an EGFR or ALK mutation positive tumour, they may be considered for treatment with targeted therapies. (C

2017 National Clinical Guidelines (Ireland)

34. Questionnaire Breakoff and Item Nonresponse in Web-Based Questionnaires: Multilevel Analysis of Person-Level and Item Design Factors in a Birth Cohort. Full Text available with Trip Pro

age (adjusted odds ratio 1.40, 95% CI 1.05-1.88), lower educational level (adjusted odds ratio [OR] 1.53, 95% CI 1.23-1.90), and earlier stage of pregnancy (adjusted OR 3.01, 95% CI 2.31-3.92) were positively associated with questionnaire breakoff. Of the 1,062,519 applicable items displayed for the participants, 22,831 were not responded to (overall prevalence of item nonresponse 2.15%). Item nonresponse was positively associated with older age (adjusted OR 1.25, 95% CI 1.14-1.38), being (...) Questionnaire Breakoff and Item Nonresponse in Web-Based Questionnaires: Multilevel Analysis of Person-Level and Item Design Factors in a Birth Cohort. Web-based questionnaires are increasingly used in epidemiologic studies, as traditional methods are facing a decrease in response rates and an increase in costs. However, few studies have investigated factors related to the level of completion of internet-based epidemiologic questionnaires.Our objective was to identify person-level

2018 Journal of medical Internet research

35. Adaptation of the Ages and Stages Questionnaire for Remote Aboriginal Australia. (Abstract)

Adaptation of the Ages and Stages Questionnaire for Remote Aboriginal Australia. A key challenge to providing quality developmental care in remote Aboriginal primary health care (PHC) centers has been the absence of culturally appropriate developmental screening instruments. This study focused on the cross-cultural adaptation of the Ages and Stages Questionnaires, 3rd edition (ASQ-3), with careful attention to language and culture. We aimed to adapt the ASQ-3 for use with remote dwelling

2014 Qualitative Health Research

36. Developmental screening in a Canadian First Nation (Mohawk): psychometric properties and adaptations of ages & stages questionnaires (2nd edition). Full Text available with Trip Pro

Developmental screening in a Canadian First Nation (Mohawk): psychometric properties and adaptations of ages & stages questionnaires (2nd edition). The need for early intervention tools adapted to the First Nation culture is well documented. However, standards derived from First Nation communities are absent from the literature. This study examines the psychometric properties of an adaptation of a caregiver-completed screening tool, the Ages & Stages Questionnaires (ASQ), for the Mohawk (...) population.Participants who completed the questionnaires include 17 teachers, along with the parents of 282 children (130 girls and 152 boys) between the ages of 9 and 66 months who attend the Child and Family Center Mohawk Territory, Quebec.For the internal consistency of the four questionnaires (36-, 42-, 48- and 54-month intervals), Cronbach's alphas varied between .61 and .84. Five results were below 0.60: "gross motor" (Q36 and Q42), "problem solving" (Q36) and "personal-social" (Q36 and Q42). A comparison

2014 BMC Pediatrics

37. Standardized motor tests and questionnaires predicting Developmental Coordination Disorder (DCD) before the age of five: a systematic review

Standardized motor tests and questionnaires predicting Developmental Coordination Disorder (DCD) before the age of five: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne (...) ). In case an outcome is measured at multiple time points, data from the time point where efficacy is highest will be included. ">Methods for data extraction Example: Experimental groups, control group(s) and number of animals per group. ">Data to be extracted: study design Example: Species, sex, weight, age, co‐morbidity, anaesthetic agent used, method of induction of cardiac ischemia, duration of ischemia and duration of reperfusion (if applicable). ">Data to be extracted: animal model Example: Dose

2018 PROSPERO

38. Dyspepsia Amongst End Stage Renal Disease Undergoing Hemodialysis: Views from a Large Tertiary Care Center Full Text available with Trip Pro

Dyspepsia Amongst End Stage Renal Disease Undergoing Hemodialysis: Views from a Large Tertiary Care Center Gastrointestinal symptoms are common in patients with end stage renal disease (ESRD) among which dyspepsia is frequently observed. The aim of the study was to determine the frequency and associations of dyspepsia in ESRD patients using the Leeds questionnaire.All ESRD patients on maintenance hemodialysis were consecutively enrolled in the study. Leeds questionnaire was used to interrogate (...) the patients for the assessment of dyspepsia. Mean and standard deviation were calculated for age, body mass index (BMI), disease duration and number of hemodialysis sessions. Independent t-test and Chi square tests were used for statistical analysis.Total number of patients was 200, out which 118 (59.3%) were male. The mean age was of 41.4 years. According to the Leeds questionnaire, dyspepsia was present in 62 (63.9%) patients. Younger patients (age 20-40 years) more frequently had dyspeptic symptoms

2018 Journal of translational internal medicine

39. Evaluation of Eat Well Keep Active (Stage 2)

Evaluation of Eat Well Keep Active (Stage 2) December 2016 Evaluation of Eat Well Keep Active (Stage 2)Eat Well Keep Active Report Stage 2 2016 Roma Robertson and Dr Ruth Jepson, SCPHRP This report describes the findings of a prospective evaluation involving participants in two CHANGES Eat Well – Keep Active courses (starting in November 2013 and June 2014). Acknowledgements We would like to thank all the Eat Well – Keep Active Course attendees who completed our questionnaires. We would also (...) of effects seen in Stage 1 • determine whether these effects were maintained over the longer term • determine which effects are maintained over the longer term and which are not. 6Eat Well Keep Active Report Stage 2 2016 MethodsEat Well Keep Active Report Stage 2 2016 This stage of the evaluation used quantitative (longitudinal postal questionnaires) methods. The Stage 1 questionnaire was amended and piloted on an Eat Well - Keep Active course which started on June 6th 2013. The responses raised concerns

2016 Scottish Collaboration for Public Health Research & Policy

40. Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease

Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Capacity to consent to participate in the study as assessed using the Evaluation to Sign Consent tool and investigator judgment Age 25 to 65 years, inclusive, at the time of signing Informed Consent Form Early manifest, Stage I or Stage II HD (defined as TFC of 7-13, inclusive) Genetically confirmed disease (CAG repeat length ≥ 36 in huntingtin gene by direct DNA testing) Body mass index ≥18 and ≤32 kg/m2; total body weight >50 kg Ability (...) Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>